A Medical Device Daily

Greatbatch (Clarence, New York) reported signing an agreement to acquire Quan Emerteq (Blaine, Minnesota) for about $55 million in cash. Quan Emerteq makes single-use medical device products for the vascular, cardiac rhythm management and neurostimulation markets.

The company anticipates that Quan Emerteq will have annual sales in the range of $20 million-$24 million for 2007. Excluding one-time purchase accounting adjustments, such as in-process R&D charges, earnings are expected to be neutral in 2007 and 2008 and accretive thereafter.

“The acquisition of Quan Emerteq expands our vascular market presence into the peripheral, coronary and neurovascular markets and broadens our existing CRM and neurostimulation product offerings,” said Thomas Hook, Greatbatch president/CEO. “This acquisition provides revenue growth opportunities to sell our expanded product portfolio to existing customers as well as diversifies our customer base with the addition of several new blue chip medical device companies. The addition of Quan Emerteq to our existing Enpath [Plymouth, Minnesota] business creates critical mass in the growing vascular market.”

The company expects to close the purchase some time in November.

Greatbatch is a developer of critical components used in medical devices for the cardiac rhythm management, neurostimulation, vascular and interventional radiology markets.

Phase Forward (Waltham, Massachusetts), a provider of data management solutions for clinical trials and drug safety, reported acquiring privately held Green Mountain Logic (GML; Montpelier, Vermont) for $5.25 million in cash.

The company is a vendor of process automation software for managing Phase I clinical trials. GML, which was founded in 1998, will continue to operate from its Vermont offices, and John Rosenblum, its president, will become a Phase Forward VP responsible for GML products.

GML’s primary product is LabPas CT, which manages clinic workflow and information from the subject recruiting process through data collection and sample management during Phase I clinical trials. The LabPas CT product helps to link subjects with their laboratory samples, matching barcodes on subject wristbands and the appropriate samples to help ensure data integrity.

Phase Forward said it plans to integrate this technology with its eClinical Suite with the goal of improving the efficiency and effectiveness of Phase I trials as well as speeding time to data lock.

In other dealmaking news:

• IsoTis (Irvine, California), an orthobiologics company, reported that its stockholders approved the company’s $51 million acquisition by Integra Lifesciences Holdings (Plainsboro, New Jersey), at a special meeting.

The acquisition, which was first disclosed in January (Medical Device Daily, Jan. 31, 2007), is expected to close shortly, followed by settlement of the acquisition price of $7.25 in cash per share.

Following the merger, shares of IsoTis stock will cease to be listed on Nasdaq, and the company will become a wholly-owned subsidiary of Integra.

Integra said the merger will make it one of the largest companies in the world focused on advanced technology in orthobiologics. Its product offerings will include brands, such as Integra Dermal Regeneration Template, DuraGen Dural Graft Matrix, Integra Mozaik Osteoconductive Scaffold, NeuraGen Nerve Guide and the Accell family of demineralized bone matrix products, DynaGraft II and OrthoBlast II.

IsoTis develops products for the treatment of musculoskeletal diseases and disorders. Its current orthobiologics products are bone graft substitutes that are designed to promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions.

• LABSInc. (Denver) has reached an agreement with Colorado’s Bonfils Blood Center to acquire the assets of Laboratories at Bonfils — a subsidiary of the blood center. The parties signed the asset purchase agreement today and expect to close the agreement by the end of the year.

Laboratories at Bonfils, owned and operated by Bonfils Blood Center since 1998, has been a reference laboratory in transplant medicine for more than 25 years. It is a primary industry resource for donor eligibility testing for the human eye, tissue, reproductive, stem cell and solid organ transplant industry.

LABS, a nonprofit provider of bone and soft tissue allografts to local communities, will retain its own management team reporting to an independent board of directors. All current Laboratories at Bonfils staff, including senior management, PhDs and laboratory personnel, will continue to provide services to customers under the new LABS Inc. name.

• Cliniqa (San Marcos, California), a manufacturer of in vitro diagnostic products, reported the acquisition of the primary assets of Reagents Applications (San Diego), a subsidiary of Hemagen Diagnostics, (Columbia, Maryland). Terms were not disclosed.